CD8A and myeloid sarcoma: Further analysis of phenotypic markers in the CD8+ subset revealed increased GZMK (2.1-fold MS versus IIH, P = 5.5 × 10–209), PRF1 (3.1-fold, P = 6.9 × 10–105), SELL (2.6-fold, P = 7.1 × 10–67), CCL5 (1.2-fold, P = 2.3 × 10–21), and IL7R (1.3-fold, P = 1.7 × 10–6) and decreased CD69 (0.8-fold, P = 1.4 × 10–33) in the patients with MS relative to those with IIH (Figure 11C).